How do you pay?

How to pay the least

Ask for the cash price

Tafinlar

We didn’t find one.

What to do

  1. Ask your pharmacy for Tafinlar’s cash price, and one or two other pharmacies too.
  2. Tafinlar’s savings card works only with insurance from a job or one you bought.

Other ways

Free from the maker, if you qualify Novartis Patient Assistance Foundation (NPAF). Patients must have a household income of less than or equal to $81,760 (for a household size of two) to be considered for NPAF. Or call 1-800-277-2254.

See if you qualify 

Compare every option

Brand name

Tafinlar, the original

Cash priceAsk the pharmacy
Ways to save on Tafinlar

The maker’s card

Novartis Oncology Universal Co-pay Program

Savings card from Novartis

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

The card takes up to $15,000 a year off your co-pay.

Sign up on us.tafinlarmekinist.com 

Or call 1-877-577-7756.

In the maker’s words

“Eligible patients with private insurance may pay $0 per month ($0 per month for a 30-day supply of TAFINLAR and $0 for a 30-day supply of MEKINIST).”

From the maker’s offer on us.tafinlarmekinist.com, checked November 17, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized generic

There isn’t one.

Not soldThere isn’t one

Regular generic

We didn’t find one.

Not soldNone found

What it’s used for

What the FDA label says

TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

TAFINLAR is indicated, in combination with trametinib, for:

  • the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
  • the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.
  • the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
  • the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.
  • the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
  • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.

Limitations of Use: TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors.

Source: the FDA label for Tafinlar (Novartis Pharmaceuticals Corporation), May 20, 2026. Full label on DailyMed 

Good to know

  • “Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
  • Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
  • Don’t stop or change a medicine without talking to your pharmacist or prescriber.